The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.
The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.
复制标题
DOI:
10.1038/s41523-021-00259-z
复制
发表时间:
2021-05-31
影响因子:
5.9
通讯作者:
Karnoub AE
中科院分区:
文献类型:
--
作者:
Tu Z;Schmoellerl J;Mariani O;Zheng Y;Hu Y;Vincent-Salomon A;Karnoub AE
The development of triple-negative breast cancer (TNBC) is critically regulated by certain tumor-microenvironment-associated cells called mesenchymal stem/stromal cells (MSCs), which we and others have shown promote TNBC progression by activating pro-malignant signaling in neighboring cancer cells. Characterization of these cascades would better our understanding of TNBC biology and bring about therapeutics that eliminate the morbidity and mortality associated with advanced disease. Here, we focused on the emerging class of RNAs called long non-coding RNAs or lncRNAs and utilized a MSC-supported TNBC progression model to identify specific family members of functional relevance to TNBC pathogenesis. Indeed, although some have been described to play functional roles in TNBC, activities of lncRNAs as mediators of tumor-microenvironment-driven TNBC development remain to be fully explored. We report that MSCs stimulate robust expression of LINC01119 in TNBC cells, which in turn induces suppressor of cytokine signaling 5 (SOCS5), leading to accelerated cancer cell growth and tumorigenesis. We show that LINC01119 and SOCS5 exhibit tight correlation across multiple breast cancer gene sets and that they are highly enriched in TNBC patient cohorts. Importantly, we present evidence that the LINC01119-SOCS5 axis represents a powerful prognostic indicator of adverse outcomes in TNBC patients, and demonstrate that its repression severely impairs cancer cell growth. Altogether, our findings identify LINC01119 as a major driver of TNBC development and delineate critical non-coding RNA theranostics of potential translational utility in the management of advanced TNBC, a class of tumors in most need of effective and targeted therapy.
登录
查看更多内容
影响因子:
23.9
作者:
Cuiffo, Benjamin G.;Campagne, Antoine;Kamoub, Antoine E.
通讯作者:
Kamoub, Antoine E.
影响因子:
45.3
作者:
Bardia, Aditya;Mayer, Ingrid A.;Vahdat, Linda T.
通讯作者:
Vahdat, Linda T.
影响因子:
64.8
作者:
Curtis, Christina;Shah, Sohrab P.;Chin, Suet-Feung;Turashvili, Gulisa;Rueda, Oscar M.;Dunning, Mark J.;Speed, Doug;Lynch, Andy G.;Samarajiwa, Shamith;Yuan, Yinyin;Graef, Stefan;Ha, Gavin;Haffari, Gholamreza;Bashashati, Ali;Russell, Roslin;McKinney, Steven;Langerod, Anita;Green, Andrew;Provenzano, Elena;Wishart, Gordon;Pinder, Sarah;Watson, Peter;Markowetz, Florian;Murphy, Leigh;Ellis, Ian;Purushotham, Arnie;Borresen-Dale, Anne-Lise;Brenton, James D.;Tavare, Simon;Caldas, Carlos;Aparicio, Samuel
通讯作者:
Aparicio, Samuel
DOI:
10.1016/j.hbpd.2020.02.011
发表时间:
2020-12-01
影响因子:
3.3
作者:
Bi, Hua-Qiang;Li, Zhong-Hui;Zhang, Hui
通讯作者:
Zhang, Hui
DOI:
10.15252/embj.201489385
发表时间:
2014-11-03
期刊:
The EMBO journal
影响因子:
--
作者:
Hong X;Nguyen HT;Chen Q;Zhang R;Hagman Z;Voorhoeve PM;Cohen SM
通讯作者:
Cohen SM